Neoplasia最新文献

筛选
英文 中文
Advancing glioblastoma treatment by targeting metabolism 通过靶向代谢推进胶质母细胞瘤的治疗
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-03-12 DOI: 10.1016/j.neo.2024.100985
Jinyi Zhao , Xuemei Ma , Peixian Gao , Xueqi Han , Pengxiang Zhao , Fei Xie , Mengyu Liu
{"title":"Advancing glioblastoma treatment by targeting metabolism","authors":"Jinyi Zhao ,&nbsp;Xuemei Ma ,&nbsp;Peixian Gao ,&nbsp;Xueqi Han ,&nbsp;Pengxiang Zhao ,&nbsp;Fei Xie ,&nbsp;Mengyu Liu","doi":"10.1016/j.neo.2024.100985","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100985","url":null,"abstract":"<div><p>Alterations in cellular metabolism are important hallmarks of glioblastoma(GBM). Metabolic reprogramming is a critical feature as it meets the higher nutritional demand of tumor cells, including proliferation, growth, and survival. Many genes, proteins, and metabolites associated with GBM metabolism reprogramming have been found to be aberrantly expressed, which may provide potential targets for cancer treatment. Therefore, it is becoming increasingly important to explore the role of internal and external factors in metabolic regulation in order to identify more precise therapeutic targets and diagnostic markers for GBM. In this review, we define the metabolic characteristics of GBM, investigate metabolic specificities such as targetable vulnerabilities and therapeutic resistance, as well as present current efforts to target GBM metabolism to improve the standard of care.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000228/pdfft?md5=8db8e44cf2fcb3f3b9420c8035568d7f&pid=1-s2.0-S1476558624000228-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140113167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ST6GAL1 is associated with poor response to chemoradiation in rectal cancer ST6GAL1 与直肠癌化疗反应差有关
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-03-10 DOI: 10.1016/j.neo.2024.100984
Mary Smithson , Sameer Al Diffalha , Regina K. Irwin , Gregory Williams , M. Chandler McLeod , Vivek Somasundaram , Susan L. Bellis , Karin M. Hardiman
{"title":"ST6GAL1 is associated with poor response to chemoradiation in rectal cancer","authors":"Mary Smithson ,&nbsp;Sameer Al Diffalha ,&nbsp;Regina K. Irwin ,&nbsp;Gregory Williams ,&nbsp;M. Chandler McLeod ,&nbsp;Vivek Somasundaram ,&nbsp;Susan L. Bellis ,&nbsp;Karin M. Hardiman","doi":"10.1016/j.neo.2024.100984","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100984","url":null,"abstract":"<div><h3>Introduction</h3><p>Colorectal cancer is the third most common cause of cancer death. Rectal cancer makes up a third of all colorectal cases. Treatment for locally advanced rectal cancer includes chemoradiation followed by surgery. We have previously identified ST6GAL1 as a cause of resistance to chemoradiation <em>in vitro</em> and hypothesized that it would be correlated with poor response in human derived models and human tissues.</p></div><div><h3>Methods</h3><p>Five organoid models were created from primary human rectal cancers and ST6GAL1 was knocked down via lentivirus transduction in one model. ST6GAL1 and Cleaved Caspase-3 (CC3) were assessed after chemoradiation via immunostaining. A tissue microarray (TMA) was created from twenty-six patients who underwent chemoradiation and had pre- and post-treatment specimens of rectal adenocarcinoma available at our institution. Immunohistochemistry was performed for ST6GAL1 and percent positive cancer cell staining was assessed and correlation with pathological grade of response was measured.</p></div><div><h3>Results</h3><p>Organoid models were treated with chemoradiation and both ST6GAL1 mRNA and protein significantly increased after treatment. The organoid model targeted with ST6GAL1 knockdown was found to have increased CC3 after treatment. In the tissue microarray, 42 percent of patient samples had an increase in percent tumor cell staining for ST6GAL1 after treatment. Post-treatment percent staining was associated with a worse grade of treatment response (p = 0.01) and increased staining post-treatment compared to pre-treatment was also associated with a worse response (p = 0.01).</p></div><div><h3>Conclusion</h3><p>ST6GAL1 is associated with resistance to treatment in human rectal cancer and knockdown in an organoid model abrogated resistance to apoptosis caused by chemoradiation.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000216/pdfft?md5=e64d225a0ea5be563852b2212ff505da&pid=1-s2.0-S1476558624000216-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL-6 facilitates cross-talk between epithelial cells and tumor- associated macrophages in Helicobacter pylori-linked gastric carcinogenesis IL-6 在幽门螺旋杆菌相关胃癌发生过程中促进上皮细胞与肿瘤相关巨噬细胞之间的交叉对话
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-02-28 DOI: 10.1016/j.neo.2024.100981
Bingting Yu , Danny de Vos , Xiaopei Guo , SanFei Peng , Wenjie Xie , Maikel P. Peppelenbosch , Yang Fu , Gwenny M. Fuhler
{"title":"IL-6 facilitates cross-talk between epithelial cells and tumor- associated macrophages in Helicobacter pylori-linked gastric carcinogenesis","authors":"Bingting Yu ,&nbsp;Danny de Vos ,&nbsp;Xiaopei Guo ,&nbsp;SanFei Peng ,&nbsp;Wenjie Xie ,&nbsp;Maikel P. Peppelenbosch ,&nbsp;Yang Fu ,&nbsp;Gwenny M. Fuhler","doi":"10.1016/j.neo.2024.100981","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100981","url":null,"abstract":"<div><h3>Purpose</h3><p><em>Helicobacter pylori (H. pylori)</em> is a significant risk factor for development of gastric cancer (GC), one of the deadliest malignancies in the world. However, the mechanism by which <em>H. pylori</em> induces gastric oncogenesis remains unclear. Here, we investigated the function of IL-6 in gastric oncogenesis and macrophage-epithelial cell interactions.</p></div><div><h3>Methods</h3><p>We analyzed publicly available datasets to investigate the expression of <em>IL-6</em> and infiltration of M2 macrophages in GC tissues, and determine the inter-cellular communication in the context of IL-6. Human gastric epithelial and macrophage cell lines (GES-1 and THP-1-derived macrophages, respectively) were used in mono- and co-culture experiments to investigate autocrine-and paracrine induction of IL-6 expression in response to <em>H. pylori</em> or IL-6 stimulation.</p></div><div><h3>Results</h3><p>We found that IL-6 is highly expressed in GC and modulates survival. M2 macrophage infiltration is predominant in GC and drives an IL-6 mediated communication with gastric epithelium cells. <em>In vitro</em>, IL-6 triggers its own expression in GES-1 and THP-1-derived macrophages cells. In addition, these cell lines are able to upregulate each other's IL-6 levels in an autocrine fashion, which is enhanced by <em>H. pylori</em> stimulation.</p></div><div><h3>Conclusion</h3><p>This study indicates that IL-6 in the tumor microenvironment is essential for intercellular communication. We show that <em>H. pylori</em> enhances an IL-6-driven autocrine and paracrine positive feedback loop between macrophages and gastric epithelial cells, which may contribute to gastric carcinogenesis.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000186/pdfft?md5=66f78ac2b09e0475ccaa1d5ae71a143c&pid=1-s2.0-S1476558624000186-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139992903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glypican-1-targeted antibody–drug conjugate inhibits the growth of glypican-1-positive glioblastoma 甘pican-1靶向抗体-药物共轭物可抑制甘pican-1阳性胶质母细胞瘤的生长
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-02-27 DOI: 10.1016/j.neo.2024.100982
Shun Uchida , Satoshi Serada , Yuji Suzuki , Eiji Funajima , Kei Kitakami , Kazumasa Dobashi , Satomi Tamatani , Yuichi Sato , Takaaki Beppu , Kuniaki Ogasawara , Testuji Naka
{"title":"Glypican-1-targeted antibody–drug conjugate inhibits the growth of glypican-1-positive glioblastoma","authors":"Shun Uchida ,&nbsp;Satoshi Serada ,&nbsp;Yuji Suzuki ,&nbsp;Eiji Funajima ,&nbsp;Kei Kitakami ,&nbsp;Kazumasa Dobashi ,&nbsp;Satomi Tamatani ,&nbsp;Yuichi Sato ,&nbsp;Takaaki Beppu ,&nbsp;Kuniaki Ogasawara ,&nbsp;Testuji Naka","doi":"10.1016/j.neo.2024.100982","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100982","url":null,"abstract":"<div><p>Glioblastoma is the deadliest form of brain tumor. The presence of the blood–brain barrier (BBB) significantly hinders chemotherapy, necessitating the development of innovative treatment options for this tumor. This report presents the <em>in vitro</em> and <em>in vivo</em> efficacy of an antibody–drug conjugate (ADC) that targets glypican-1 (GPC1) in glioblastoma. The GPC1-ADC was created by conjugating a humanized anti-GPC1 antibody (clone T2) with monomethyl auristatin E (MMAE) <em>via</em> maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl linkers. Immunohistochemical staining analysis of a glioblastoma tissue microarray revealed that GPC1 expression was elevated in more than half of the cases. GPC1-ADC, when bound to GPC1, was efficiently and rapidly internalized in glioblastoma cell lines. It inhibited the growth of GPC1-positive glioma cell lines by inducing cell cycle arrest in the G2/M phase and triggering apoptosis <em>in vitro</em>. We established a heterotopic xenograft model by subcutaneously implanting KALS-1 and administered GPC1-ADC intravenously. GPC1-ADC significantly inhibited tumor growth and increased the number of mitotic cells. We also established an orthotopic xenograft model by intracranially implanting luciferase-transfected KS-1-Luc#19. After injecting Evans blue and resecting brain tissues, dye leakage was observed in the implantation area, confirming BBB disruption. We administered GPC1-ADC intravenously and measured the luciferase activity using an <em>in vivo</em> imaging system. GPC1-ADC significantly inhibited tumor growth and extended survival. In conclusion, GPC1-ADC demonstrated potent intracranial activity against GPC1-positive glioblastoma in an orthotopic xenograft model. These results indicate that GPC1-ADC could represent a groundbreaking new therapy for treating glioblastoma beyond the BBB.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000198/pdfft?md5=30ea273849b18d645bc33f865a23dfba&pid=1-s2.0-S1476558624000198-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139986841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations 在中国前列腺导管内癌中发现复发性 BRAF 非 V600 基因突变
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-02-27 DOI: 10.1016/j.neo.2024.100983
Jing Hu , Xinyi Chen , Feifei Sun , Lili Liu , Long Liu , Zimeng Yang , Hanwen Zhang , Zeyuan Yu , Ru Zhao , Yueyao Wang , Hui Liu , Xiaorong Yang , Fusheng Sun , Bo Han
{"title":"Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations","authors":"Jing Hu ,&nbsp;Xinyi Chen ,&nbsp;Feifei Sun ,&nbsp;Lili Liu ,&nbsp;Long Liu ,&nbsp;Zimeng Yang ,&nbsp;Hanwen Zhang ,&nbsp;Zeyuan Yu ,&nbsp;Ru Zhao ,&nbsp;Yueyao Wang ,&nbsp;Hui Liu ,&nbsp;Xiaorong Yang ,&nbsp;Fusheng Sun ,&nbsp;Bo Han","doi":"10.1016/j.neo.2024.100983","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100983","url":null,"abstract":"<div><p>While <em>BRAF</em> alterations have been established as a driver in various solid malignancies, the characterization of <em>BRAF</em> alterations in prostate cancer (PCa) has not been thoroughly interrogated. By bioinformatics analysis, we first found that <em>BRAF</em> alterations were associated with advanced PCa and exhibited mutually exclusive pattern with ERG alteration across multiple cohorts. Of the most interest, recurrent non-V600 <em>BRAF</em> mutations were found in 3 of 21 (14.3 %) PCa patients demonstrating IDC-P morphology. Furthermore, experimental overexpression of <em>BRAF<sup>K601E</sup></em> and <em>BRAF<sup>L597R</sup></em> exhibited emergence of oncogenic phenotypes with intensified MAPK signaling <em>in vitro</em>, which could be targeted by MEK inhibitors<em>.</em> Comparison of the incidence of <em>BRAF</em> alterations in IDC-P between western and Chinese ancestry revealed an increased prevalence in the Chinese population. The <em>BRAF</em> mutation may represent important genetic alteration in a subset of IDC-P, highlighting the role of MAPK signaling pathway in this subtype of PCa. To the best of knowledge, this is the first description of non-V600 <em>BRAF</em> mutation in setting of IDC-P, which may in part explain the aggressive phenotype seen in IDC-P and could also bring more treatment options for PCa patients with IDC-P harboring such mutations.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000204/pdfft?md5=ffc2fe277ab8b3fe511b61dba80b747a&pid=1-s2.0-S1476558624000204-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A deep learning based holistic diagnosis system for immunohistochemistry interpretation and molecular subtyping 基于深度学习的免疫组化解释和分子亚型整体诊断系统
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-02-26 DOI: 10.1016/j.neo.2024.100976
Lin Fan , Jiahe Liu , Baoyang Ju , Doudou Lou , Yushen Tian
{"title":"A deep learning based holistic diagnosis system for immunohistochemistry interpretation and molecular subtyping","authors":"Lin Fan ,&nbsp;Jiahe Liu ,&nbsp;Baoyang Ju ,&nbsp;Doudou Lou ,&nbsp;Yushen Tian","doi":"10.1016/j.neo.2024.100976","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100976","url":null,"abstract":"<div><h3>Background</h3><p>Breast cancer in different molecular subtypes, which is determined by the overexpression rates of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR), and Ki67, exhibit distinct symptom characteristics and sensitivity to different treatment. The immunohistochemical method, one of the most common detecting tools for tumour markers, is heavily relied on artificial judgment and in clinical practice, with an inherent limitation in interpreting stability and operating efficiency. Here, a holistic intelligent breast tumour diagnosis system has been developed for tumour-markeromic analysis, combining the automatic interpretation and clinical suggestion.</p></div><div><h3>Methods</h3><p>The holistic intelligent breast tumour diagnosis system included two main modules. The interpreting modules were constructed based on convolutional neural network, for comprehensively extracting and analyzing the multi-features of immunostaining. Referring to the clinical classification criteria, the interpreting results were encoded in a low-dimensional feature representation in the subtyping module, to efficiently output a holistic detecting result of the critical tumour-markeromic with diagnosis suggestions on molecular subtypes.</p></div><div><h3>Results</h3><p>The overexpression rates of HER2, ER, PR, and Ki67, as well as an effective determination of molecular subtypes were successfully obtained by this diagnosis system, with an average sensitivity of 97.6 % and an average specificity of 96.1 %, among those, the sensitivity and specificity for interpreting HER2 were up to 99.8 % and 96.9 %.</p></div><div><h3>Conclusion</h3><p>The holistic intelligent breast tumour diagnosis system shows improved performance in the interpretation of immunohistochemical images over pathologist-level, which can be expected to overcome the limitations of conventional manual interpretation in efficiency, precision, and repeatability.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000137/pdfft?md5=a0bfe62e5827eebf3b9ba7233d057374&pid=1-s2.0-S1476558624000137-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.” [Neoplasia Volume 23, Issue 9, September 2021, Pages 1002-1015] Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells:其抑制诱导 HR 缺失和与 PARP 抑制协同致死 "一文的更正。[肿瘤学》第 23 卷第 9 期,2021 年 9 月,第 1002-1015 页]
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-02-24 DOI: 10.1016/j.neo.2024.100978
Chinnadurai Mani , Kaushlendra Tripathi , Sandeep Chaudhary , Ranganatha R. Somasagara , Rodney P. Rocconi , Chiquito Crasto , Mark Reedy , Mohammad Athar , Komaraiah Palle
{"title":"Corrigendum to “Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.” [Neoplasia Volume 23, Issue 9, September 2021, Pages 1002-1015]","authors":"Chinnadurai Mani ,&nbsp;Kaushlendra Tripathi ,&nbsp;Sandeep Chaudhary ,&nbsp;Ranganatha R. Somasagara ,&nbsp;Rodney P. Rocconi ,&nbsp;Chiquito Crasto ,&nbsp;Mark Reedy ,&nbsp;Mohammad Athar ,&nbsp;Komaraiah Palle","doi":"10.1016/j.neo.2024.100978","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100978","url":null,"abstract":"","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000150/pdfft?md5=fda44061fb5e63883f877199466ef9da&pid=1-s2.0-S1476558624000150-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139942062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection 谁能从肺腺癌 I 期辅助化疗中获益?候选者选择的多维模型
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-02-21 DOI: 10.1016/j.neo.2024.100979
Meng-qi Jiang , Li-qiang Qian , Yu-jia Shen , Yuan-yuan Fu , Wen Feng , Zheng-ping Ding , Yu-chen Han , Xiao-long Fu
{"title":"Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection","authors":"Meng-qi Jiang ,&nbsp;Li-qiang Qian ,&nbsp;Yu-jia Shen ,&nbsp;Yuan-yuan Fu ,&nbsp;Wen Feng ,&nbsp;Zheng-ping Ding ,&nbsp;Yu-chen Han ,&nbsp;Xiao-long Fu","doi":"10.1016/j.neo.2024.100979","DOIUrl":"10.1016/j.neo.2024.100979","url":null,"abstract":"<div><h3>Background</h3><p>Despite promising overall survival of stage I lung adenocarcinoma (LUAD) patients, 10-25 % of them still went through recurrence after surgery. [1] While it is still disputable whether adjuvant chemotherapy is necessary for stage I patients. [2] IASLC grading system for non-mucinous LUAD shows that minor high-grade patterns are significant indicator of poor prognosis. [3] Other risk factors, such as, pleura invasion, lympho-vascular invasion, STAS, etc. are also related to poor prognosis. [4-6] There still lack evidence whether IASLC grade itself or together with other risk factors can guide the use of adjuvant therapy in stage I patients. In this article, we tried to establish a multi-variable recurrence prediction model for stage I LUAD patients that is able to identify candidates of adjuvant chemotherapy.</p></div><div><h3>Methods</h3><p>We retrospectively collected patients who underwent lung surgery from 2018.8.1 to 2018.12.31 at our institution and diagnosed with lung adenocarcinoma pT1-2aN0M0 (stage I). Clinical data, manifestation on CT scan, pathologic features, driver gene mutations and follow-up information were collected. Cox proportional hazards regression analyses were performed utilizing the non-adjuvant cohort to predict disease free survival (DFS) and a nomogram was constructed and applied to the total cohort. Kaplan-Meier method was used to compare DFS between groups. Statistical analysis was conducted by R version 3.6.3.</p></div><div><h3>Findings</h3><p>A total of 913 stage I LUAD patients were included in this study. Median follow-up time is 48.1 months.4-year and 5-year DFS are 92.9 % and 89.6 % for the total cohort. 65 patient experienced recurrence or death. 4-year DFS are 97.0 %,94.6 % and 76.2 %, and 5-year DFS are 95.5 %, 90.0 % and 74.1 % in IASLC Grade1, 2 and 3, respectively(p &lt; 0.0001). High-risk patients defined by single risk factors, such as, IASLC grade 3, pleura invasion, STAS, less LN resected could not benefit from adjuvant therapy. A LASSO-COX regression model was built and patients are divided into high-risk and low-risk groups. In the high-risk group, patients underwent adjuvant chemotherapy have longer DFS than those who did not (p = 0.024), while in the low-risk group, patients underwent adjuvant chemotherapy have inferior DFS than those who did not (<em>p</em> &lt; 0.001).</p></div><div><h3>Interpretation</h3><p>IASLC grading is a significant indicator of DFS, however it could not guide adjuvant therapy in our stage I LUAD cohort. Growth patterns and T indicators together with other risk factors could identify high-risk patients that are potential candidate of adjuvant therapy, including some stage IA LUAD patients.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000162/pdfft?md5=bd2ae44ddcd51e1ee9c73cd124f793f8&pid=1-s2.0-S1476558624000162-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139918371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single cell analysis unveils the commonality and heterogeneity between nasopharyngeal and oropharyngeal carcinoma 单细胞分析揭示鼻咽癌和口咽癌的共性和异质性
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-02-20 DOI: 10.1016/j.neo.2024.100980
Liping Wang , Shuang Li , Xinran Li , Guangzheng Zhuo , Qian Zhang , Guohong Liu , Yunbao Pan
{"title":"Single cell analysis unveils the commonality and heterogeneity between nasopharyngeal and oropharyngeal carcinoma","authors":"Liping Wang ,&nbsp;Shuang Li ,&nbsp;Xinran Li ,&nbsp;Guangzheng Zhuo ,&nbsp;Qian Zhang ,&nbsp;Guohong Liu ,&nbsp;Yunbao Pan","doi":"10.1016/j.neo.2024.100980","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100980","url":null,"abstract":"<div><p>Nasopharyngeal carcinoma (NPC) and oropharyngeal carcinoma (OPC) are subtypes of head and neck cancer with different treatment effects due to the heterogeneity of tumor microenvironments. This study was to investigate the distinctive tumor microenvironments of NPC and OPC. Analyzing single-cell data from 10 cases of each subtype, we reveal significant differences in cellular composition, with NPC microenvironment dominated by T/NK and B cells, and OPC characterized by prevalent epithelial cells and fibroblasts. Dynamic transitions of CD8 T cells are observed in both tumor types, involving shifts from naivety to cytotoxicity, proliferation, and eventual exhaustion/exhausted states. Additionally, Tregs exhibit heightened proliferative abilities in later developmental stages, concomitant with exhaustion. These highly proliferative T cells and Tregs manifest elevated glycolysis and lactate metabolism activities. Furthermore, we explore intercellular communication between glycolytic malignant epithelial cells and these proliferative T cells. These findings offer comprehensive insights into the heterogeneity of tumor microenvironments and provide a solid foundation for future therapeutic strategies and targeted interventions.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000174/pdfft?md5=59376fcd78eee7b7d5cd3a592ffd5d6c&pid=1-s2.0-S1476558624000174-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139908521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors 以骨髓瘤代谢为靶点:异常代谢如何导致多发性骨髓瘤进展和对蛋白酶体抑制剂产生抗药性
IF 4.8 2区 医学
Neoplasia Pub Date : 2024-02-16 DOI: 10.1016/j.neo.2024.100974
Xiang Zhou , Rui He , Wei-Xin Hu, Saiqun Luo, Jingping Hu
{"title":"Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors","authors":"Xiang Zhou ,&nbsp;Rui He ,&nbsp;Wei-Xin Hu,&nbsp;Saiqun Luo,&nbsp;Jingping Hu","doi":"10.1016/j.neo.2024.100974","DOIUrl":"https://doi.org/10.1016/j.neo.2024.100974","url":null,"abstract":"<div><p>Multiple myeloma is a hematological malignancy that has evolved from antibody-secreting B lymphocytes. Like other types of cancers, myeloma cells have acquired functional capabilities which are referred to as “Hallmarks of Cancer”, and one of their most important features is the metabolic disorders. Due to the high secretory load of the MM cells, the first-line medicine proteasome inhibitors have found their pronounced effects in MM cells for blocking the degradation of misfolded proteins, leading to their accumulation in the ER and overwhelming ER stress. Moreover, proteasome inhibitors have been reported to be effective in myeloma by targeting glucose, lipid, amino acid metabolism of MM cells. In this review, we have described the abnormal metabolism of the three major nutrients, such as glucose, lipid and amino acids, which participate in the cellular functions. We have described their roles in myeloma progression, how they could be exploited for therapeutic purposes, and current therapeutic strategies targeting these metabolites, hoping to uncover potential novel therapeutic targets and promote the development of future therapeutic approaches.</p></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1476558624000113/pdfft?md5=b46bea063ea215c71f9a03e0f51003ae&pid=1-s2.0-S1476558624000113-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139743879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信